Episode #164 High Truths on Drugs and Addiction with Dr. Meg Haney and Cannabis Addiction TreatmentEpisode #164 High Truths on Drugs and Addiction with Dr. Meg Haney and Cannabis Addiction Treatment
High Truths on Drugs and Addiction
Is there treatment and hope for people with cannabis use disorder? There is always hope, and there are more treatment options on the horizon. Dr. Meg Haney shares information on AEF0117, an inhibitor of the CB1 receptor. We discuss a young man who struggles with cannabis use disorder and mental health that his parents attribute to high potent THC products. Dr. Margaret (Meg) Haney is a Professor of Neurobiology (in Psychiatry) at the Columbia University Medical Center, where she is the Director of the Cannabis Research Laboratory and Co-Director of the Substance Use Research Center. Her research focuses on human laboratory models of cannabis and cocaine use disorders and the assessment of novel pharmacologic and immunologic approaches to treat these disorders. Her particular interest is to define the factors that contribute to the daily use of drugs. Her publications to date have largely focused on: (1) the positive and negative reinforcing effects of cocaine and cannabis, (2) the effects of medications on cannabis and cocaine self-administration, (3) predictors of cannabis withdrawal and relapse, (4) the potential medical benefits of different cannabinoids, alone and in combination with opioid medications. Dr. Haney's research has been continuously supported by NIDA since 1999. She is internationally recognized for her expertise, particularly regarding cannabis use disorder. She is an author on more than 150 articles in peer-reviewed journals and 12 book chapters, is an Associate Editor for Cannabis and Cannabinoid Research, an advisory editor for Psychopharmacology, a longstanding participant in NIH review groups, and is a fellow in the American College of Neuropsychopharmacology and recent past President of the College on Problems of Drug Dependence. Dr. Haney frequently provides media interviews, including television (CNBC, NBC, CBS), newspapers (e.g., NY Times, Wall St. Journal), magazines (e.g., Time, New York Magazine), radio (WNYC, NPR), podcasts (Science Rules! with Bill Nye) and digital media (seeker.com).
1:08:30•12 Feb 2024
Cannabis Use Disorder: Insights and Hope with Dr. Meg Haney
Episode Overview
- Dr. Meg Haney's groundbreaking research on cannabis withdrawal and treatment options
- Insights into the biological effects of high-potency THC on the brain
- Discussions on the challenges of studying cannabis use disorder and mental health
- Exploration of potential medications for cannabis-related issues
- Importance of informed decision-making and public awareness on cannabis use
“Your cannabis use is not going to help. Yeah, yeah, yeah. One large study, like almost 7 million people in Denmark, showed that if we could target just men between the ages 21 to 30, if we just had that one target and prevented cannabis use disorder in that subsegment of the population, we would have 30% less schizophrenia.”
What happens when the highs of cannabis use turn into a daily struggle? Dr. Meg Haney, a neurobiology professor at Columbia University Medical Center, joins Dr. Roneet Lev on 'High Truths on Drugs and Addiction' to explore this question. Dr. Haney shares her extensive research on cannabis use disorder, including the effects of high-potency THC products and the challenges of withdrawal.
She introduces AEF0117, a promising new treatment targeting the CB1 receptor, and discusses its potential to help those battling addiction. The episode also touches on a young man's journey with cannabis use and mental health issues, offering a personal glimpse into the real-world impact of Dr. Haney's work. Whether you're grappling with cannabis use yourself or supporting someone who is, this episode offers valuable insights and hope for the future.

Do you want to link to this podcast?
Get the buttons here!
More From This Show
The latest episodes from the same podcast.
Related Episodes
Similar episodes from other shows in the catalogue.
